Pharmacokinetics and Safety of Moxifloxacin

Update Il y a 4 ans
Reference: NCT01329250

Woman and Man

Extract

The main objective of this prospective clinical trial is to compare pharmacokinetics and safety and tolerability of a standard dose (400 mg) with an escalated dose (600 mg; 800 mg) of moxifloxacin (MFX). This clinical trial will provide important safety information on MFX in a higher dosage in TB patients.


Inclusion criteria

  • Tuberculosis

Links